ValiRx narrows losses on lower R&D, admin spend
Clinical-stage drug development company ValiRx narrowed full-year losses after it cut back on R&D and administrative spending.
Pre-tax losses for the year through December amounted...
Tue, 27/04/2021 - 08:46